Business Context and Reporting Period
Company: AngioDynamics, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Thirteen and twenty-six weeks ended November 26, 2005.
Business Overview: AngioDynamics designs, develops, manufactures, and markets innovative medical devices for minimally invasive, image-guided procedures to treat peripheral vascular disease (PVD). The company operates in a single segment focused on peripheral vascular disease.
Key Financial Metrics
| Metric (in thousands) | 13 Weeks Ended Nov 26, 2005 |
26 Weeks Ended Nov 26, 2005 |
26 Weeks Ended Nov 27, 2004 |
|---|---|---|---|
| Net Sales | $18,707 | $35,074 | $27,507 |
| Gross Profit | $10,846 | $20,366 | $15,057 |
| Gross Margin % | 58.0% | 58.1% | 54.7% |
| Operating Profit | $2,399 | $4,312 | $3,063 |
| Net Income | $1,655 | $2,948 | $1,797 |
| Diluted EPS | $0.13 | $0.23 | $0.15 |
| Cash from Operations | N/A | $2,381 | $1,277 |
| Total Assets | $64,238 | $64,238 | $59,672 |
| Total Liabilities | $9,950 | $9,950 | $10,562 |
| Long-Term Debt | $2,845 | $2,845 | $2,935 |
| Cash & Equivalents | $13,043 | $13,043 | $14,498 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 29.9% ($4.3 million) for the quarter and 27.5% ($7.6 million) for the six-month period compared to the prior year. Growth was driven by increased unit sales of new products, specifically the Morpheus CT PICC (vascular access), VenaCure (varicose vein treatment), and hemodialysis products.
- Margin Expansion: Gross margin improved to 58.0% (quarter) and 58.1% (six months) from 56.0% and 54.7% in the prior year periods, respectively. This was attributed to a favorable product mix shift toward higher-margin items and production efficiencies.
- Profitability: Net income rose 59.8% for the quarter and 64.1% for the six-month period. The effective tax rate decreased to 36.5% (quarter) and 37.0% (six months) from 42.9% and 42.0% in the prior year, largely due to research and development tax credits.
- Operating Expenses: Selling and marketing expenses increased 37.9% (quarter) due to expanded sales territories and commissions. General and administrative expenses rose 23.5% (quarter) due to costs associated with operating as an independent public company (e.g., Sarbanes-Oxley compliance, insurance, director fees).
Guidance, Outlook, Risks, and Unusual Items
- Strategic Initiatives: The company entered a Supply and Distribution Rights Agreement with Bioniche Pharma Group Limited in October 2005 to exclusively distribute Sotradecol, a sclerosing drug for varicose veins. A non-refundable fee of $2.3 million was paid/accrued, recorded as an intangible asset.
- Liquidity and Capital: On November 23, 2005, the company replaced its $3.0 million line of credit with a new $7.5 million facility. No amounts were outstanding under the new facility as of the reporting date. The company maintains a strong liquidity position with a current ratio of 7.1 to 1.
- Equity Restrictions: Due to the spin-off from E-Z-EM, Inc., the company is restricted from issuing more than approximately 5.5 million shares of common stock until November 2006 to preserve tax-free treatment of the distribution.
- Legal Proceedings:
- Diomed v. AngioDynamics: Allegations of patent infringement regarding VenaCure products. The company filed a motion for summary judgment of non-infringement. A potential loss range of $674,000 to $5.4 million is disclosed if the outcome is unfavorable.
- VNUS Medical Technologies v. AngioDynamics: Allegations of patent infringement. The company disputes the claims and is seeking indemnification from its supplier, biolitec, Inc., though biolitec has disputed its obligation to indemnify.
- Forward-Looking Statements: Management expects continued growth in gross margins and revenue but notes that selling expenses will increase as the sales force expands to 70 representatives over the next three years.
Investor Verification Checklist
- Legal Exposure: Verify the status of the Diomed and VNUS patent infringement lawsuits and the outcome of the indemnification dispute with supplier biolitec, Inc.
- Product Mix Sustainability: Assess whether the improved gross margins (58.1%) are sustainable or if they are temporary due to the specific mix of new high-margin products.
- Equity Financing Constraints: Confirm the impact of the 5.5 million share issuance limit (until Nov 2006) on the company's ability to fund future acquisitions or capital needs.
- Debt Covenants: Review the terms of the new $7.5 million line of credit, specifically the interest rate structure (LIBOR + 175 bps) and covenants regarding financial condition.
- Intangible Asset Amortization: Monitor the amortization schedule of the $2.3 million Bioniche distribution rights fee and its impact on future operating expenses.